Taysha Gene Therapies (TSHA) Interest Expenses (2019 - 2026)

Taysha Gene Therapies (TSHA) has 8 years of Interest Expenses data on file, last reported at $57.2 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 573.19% year-over-year to $57.2 million; the trailing twelve-month figure through Mar 2026 stood at $57.2 million (up 573.19% YoY), and the FY2025 full-year result was $81.7 million, down 28.44% from the prior year.
• Interest Expenses advanced to $57.2 million in Q1 2026, from $12000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $57.2 million in Q1 2026 to a low of -$3.9 million in Q4 2024.
• A 5-year average of $13.7 million and a median of $9.6 million in 2024 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses jumped 4226.65% in 2023 and tumbled 401.32% in 2024, its largest moves.
• Tracing TSHA's Interest Expenses over 5 years: stood at $2.0 million in 2022, then sank by 36.91% to $1.3 million in 2023, then plunged by 401.32% to -$3.9 million in 2024, then surged by 100.31% to $12000.0 in 2025, then soared by 476683.33% to $57.2 million in 2026.
• Business Quant data shows TSHA's Interest Expenses at $57.2 million in Q1 2026, $12000.0 in Q4 2025, and $31.1 million in Q3 2025.